Podcast Episodes
Back to Search
Episode 513: Trials and Tribulations of Investigator-initiated Research
Bishoy Faltas joins Brian and Tom to discuss his IIT in bladder cancer. The intended discussion of the trials turned into an insightful discussion on…
3 months, 1 week ago
Episode 512: ENZA-P Nature Medicine translational data
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
3 months, 2 weeks ago
Episode 510: ADCs in Prostate Cancer
Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development …
4 months, 1 week ago
Episode 509: ASCO 2026 Review
This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, a…
4 months, 2 weeks ago
Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer
Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about th…
4 months, 3 weeks ago
Episode 507: ASCO 2026 - TALAPRO-3
Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer…
4 months, 3 weeks ago
Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?
This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer c…
4 months, 3 weeks ago
Episode 505 : ASCO 2026 - RAMPART
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data …
4 months, 3 weeks ago
Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer
This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV30…
4 months, 3 weeks ago
Episode 499: APCCC 2026 - Radioligands in Prostate Cancer
This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prost…
4 months, 4 weeks ago